Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 30 Neoplasms 11 Thyroid Neoplasms 7 Thyroid Carcinoma, Anaplastic 6 Brain Neoplasms 6 Multiple Myeloma 4 Glioma 4 Colorectal Neoplasms 4 Hematologic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Thyroid Cancer, Papillary 2 Skin Neoplasms 2 Neoplasm Metastasis 2 Lymphoma 2 Glioblastoma 2 Astrocytoma 2 Ameloblastoma 2 Adenocarcinoma, Follicular 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Stomach Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumor 1 Rectal Neoplasms 1 Rare Malignant Neoplasm 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1

Interventions

Radiotherapy 2 Proton Therapy 2 Mental Status and Dementia Tests 2 trametinib 1 tozuleristide 1 tovorafenib 1 tocilizumab 1 dabrafenib 1 cobimetinib 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Vemurafenib 1 Transurethral Resection of Bladder 1 Surgical Procedures, Operative 1 Qsymia 1 Phentermine 1 Oxytocin 1 Methionine 1 Memantine 1 Medication Errors 1 Ginkgo biloba extract 1 Exenatide 1 Donepezil 1 Contrast Media 1 CKD732 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Craniopharyngioma × dabrafenib × Clear all

NCT05525273 2024-02-14

Swecranio

Skane University Hospital

Phase 2 Recruiting

Craniopharyngioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡